Difference between Enbrel and Benepali treatment groups in ‘hepatobiliary disorders’

Annals of the Rheumatic Diseases

Volumn 75, Issue 10, 2016, Pages e64-

  Scheinberg, Morton ^a   Azevedo, Valderilio ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ETANERCEPT; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978765827     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210101     Document Type: Letter

References (2)

1. Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2015; Published Online First 6 July 2015. doi:10.1136/annrheumdis-2015-207588
2. http://www.ema.europe.eu/docs/en_GB/document_library/EPAR_Public_assesssment_report/human/004007/WC500200380pdf